The Nucleix team is at the annual meeting of the American Urological Association (AUA) in San Antonio! Bladder EpiCheck® is FDA 510(k) cleared in the United States for bladder cancer recurrence and CE-marked in Europe for primary and recurrent bladder cancer and UTUC #AUA24

We'll be presenting results from our pivotal clinical study evaluating the performance of Bladder EpiCheck® as a non-invasive & objective novel methylation-based PCR urine test for the surveillance of #NMIBC recurrence at #AUA24. bit.ly/4bke27K @uroweb Amer. Urol. Assn.

We recently presented results from our North American pivotal clinical study demonstrating the potential of Bladder EpiCheck® to improve disease recurrence detection in #NMIBC surveillance at the Amer. Urol. Assn. Annual Meeting. Learn more: bit.ly/3QzurgG #AUA24

Let's meet during the 11th Scottisch Bladder Cancer Symposium on Non Muscle Invasive Bladder, May 30-31, 2024, in Edinburgh, Scotland. As always, the latest updates on Bladder EpiCheck®; What else...

Let's meet during the 11th Scottisch Bladder Cancer Symposium on Non Muscle Invasive Bladder, May 30-31, 2024, in Edinburgh, Scotland. As always, the latest updates on Bladder EpiCheck®; What else...

Please check out the webinar featuring Yann NEUZILLET and Pierre-Jean Lamy Groupe INOVIE discussing Bladder EpiCheck® and its involvement in the Association Française d'Urologie - AFU Registry. urofrance.org/simplenews/bla…

Glad to be part of the ongoing second edition of the European onco-urological event, UROonco24! 🌟 Currently taking place in the historic city of Budapest, Hungary from 20-22 June 2024. Stay connected for the latest updates on Bladder EpiCheck®, What else......

This week, our CSO, Mathias Ehrich, will be presenting at the Cambridge Healthtech Institute Next Gen Dx Summit. Learn more about his presentation on early cancer surveillance and how we are aiming to revolutionize cancer treatment with earlier disease detection here: bit.ly/3M1R8aC

We've announced a commercial agreement w/ A. Menarini Diagnostics for the exclusive distribution of Bladder EpiCheck® in Europe. Learn more about our aim to accelerate the adoption of Bladder EpiCheck® to transform bladder cancer care. bit.ly/3z1vTTB European Society of Pathology (ESP)

Last month, our CSO, Mathias Ehrich, presented at Cambridge Healthtech Institute’s Next Gen Dx Summit. Thank you to all who attended our session to learn more about our approach to detect cancer earlier when treatment can be most effective for patients.

#DYK lung cancer is the leading cause of cancer deaths in the US, but less than 1 in 10 eligible individuals adhere to screening guidelines? Learn more this National Lung Cancer Screening Day about our work to detect cancer early in high-risk populations. bit.ly/3YsGcIQ

Next week, our CEO, Chris Hibberd, will be presenting at the Piper Sandler Healthcare Conference. Connect with us onsite for 1x1 meetings to learn more about our #liquidbiopsy tests that aim to detect #cancer earlier, when treatment can be most effective for patients.

Glad to be attending Bladder-CAT in Sitges, Spain, from February 21-22. Stay tuned for updates on Bladder EpiCheck®. What else...

Let's meet during the ESU-ESOU Masterclass on Non-muscle-invasive bladder cancer, which will take place on February 27 & 28, 2025 in Prague, Czech Republic. As always, the latest updates on Bladder EpiCheck®; What else... #innovation #Oncology #bladdercancer

In partnership with NHS Lothian, we presented data on the potential of Bladder EpiCheck® at #EAU25, showcasing the potential of the test to increase the detection of High-Grade recurrences in #NMIBC patients by 65%. businesswire.com/news/home/2025… Prof Param Mariappan FRCS(Urol), PhD #innovation

Let's meet during the MIBC Masterclass, Amsterdam, the Netherlands on April 10-11, 2025. As always, the latest updates on Bladder EpiCheck®; What else...

This week, we’re presenting an abstract showcasing the performance and clinical utility of Bladder EpiCheck® in #NMIBC monitoring at the Amer. Urol. Assn. 2025 Annual Meeting. Learn more: businesswire.com/news/home/2025… #AUA25

#DidYouKnow bladder cancer is the 6th most common cancer in the US & the 5th most common cancer in Europe? At Nucleix, our non-invasive, urine-based test, Bladder EpiCheck® provides physicians & their patients with a simple, non-invasive urine test to detect disease recurrence.

Let's meet during the 12th Scottish Bladder Cancer Symposium, May 29-30 in Edinburgh. Once again, the latest updates on Bladder EpiCheck®. Always a pleasure meeting Prof Prof Param Mariappan FRCS(Urol), PhD and Prof Ashish M. Kamat, MD, MBBS Menarini Diagnostics UK NHS Lothian

Let's meet during the 3rd UROonco, June 19-21 in Seville. Once again, the latest updates on Bladder EpiCheck®. Always a pleasure meeting Dr Roberto Contieri and Dr MATTIA NICOLA SANGALLI European Association of Urology (EAU) #Oncology